You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

59 Results
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
  • medroxyprogesterone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
medroxyprogesterone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2016
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant, Adjuvant
Drugs Used:
DOCEtaxel,
DOXOrubicin,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2016
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
  • flutamide
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
flutamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2016
Guidelines and Advice
Status: Current
Version: 2
Mar 2022
Guidelines and Advice
Status: Current
Version: 2
Mar 2022
Statistical Reports
Sep 2016
Statistical Reports
Sep 2016
Statistical Reports
Jun 2016
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    gilteritinib - Relapsed or Refractory FLT3-mutated acute myeloid leukemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
gilteritinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2022
Regimen
Cancer Type:
Hematologic, 
Leukemia - Hairy Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
vemURAFenib (Unfunded),
riTUXimab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2022
Guidelines and Advice
Status: Current
ID: GL 16-3
Version: 3
Mar 2022

Pages